Moderna lines up melanoma and myeloma data for ASCO in Chicago

robot
Abstract generation in progress

Moderna announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2026 ASCO Annual Meeting. The presentations include a 5-year update on intismeran plus pembrolizumab in resected melanoma, and two poster presentations covering intismeran autogene as adjuvant therapy in melanoma and mRNA-2808 in multiple myeloma. Moderna will also host a live investor webcast on June 1 to discuss these presentations.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin